Published in J Natl Cancer Inst on January 08, 2008
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. Mol Cell (2013) 2.79
Regulation of mTORC1 by amino acids. Trends Cell Biol (2014) 2.64
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene (2009) 2.14
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens (2009) 1.73
Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol (2010) 1.70
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol (2012) 1.61
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
Disruption of tubular Flcn expression as a mouse model for renal tumor induction. Kidney Int (2015) 1.46
Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J Clin Pathol (2012) 1.37
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol Cancer (2010) 1.30
Functional aspects of primary cilia in signaling, cell cycle and tumorigenesis. Cilia (2013) 1.28
Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription. Oncogene (2011) 1.23
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One (2010) 1.23
CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer (2009) 1.21
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood (2012) 1.17
Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer Inst (2012) 1.16
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol (2010) 1.12
Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies. Fam Cancer (2013) 1.12
Monitoring of tumor promotion and progression in a mouse model of inflammation-induced colon cancer with magnetic resonance colonography. Neoplasia (2009) 1.11
Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol (2009) 1.10
Pulmonary manifestations of Birt-Hogg-Dubé syndrome. Fam Cancer (2013) 1.10
Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A (2009) 1.10
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One (2012) 1.08
Multiple amino acid sensing inputs to mTORC1. Cell Res (2015) 1.06
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics (2010) 1.06
Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. Nat Rev Urol (2015) 1.04
Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet (2013) 1.04
Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol (2012) 1.00
Discovery of new Longin and Roadblock domains that form platforms for small GTPases in Ragulator and TRAPP-II. Small GTPases (2013) 0.98
Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Hum Mol Genet (2012) 0.98
Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue. Cilia (2013) 0.94
Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. Cell Rep (2014) 0.94
Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proc Natl Acad Sci U S A (2015) 0.92
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
Genetic characterization of the Drosophila birt-hogg-dubé syndrome gene. PLoS One (2013) 0.87
Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87
Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cells. J Exp Clin Cancer Res (2013) 0.87
The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue. Genes Dev (2016) 0.85
Human folliculin delays cell cycle progression through late S and G2/M-phases: effect of phosphorylation and tumor associated mutations. PLoS One (2013) 0.84
Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. PLoS One (2013) 0.84
Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Hum Mol Genet (2014) 0.83
Targeting the mTOR pathway in Chromophobe Kidney Cancer. J Cancer (2012) 0.82
Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. Physiol Rep (2014) 0.82
Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial. PLoS One (2014) 0.81
The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis. Hum Mol Genet (2012) 0.81
Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours. Eur J Hum Genet (2013) 0.81
The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Rep (2017) 0.79
Conserved regulators of Rag GTPases orchestrate amino acid-dependent TORC1 signaling. Cell Discov (2016) 0.79
Amino acid management in cancer. Semin Cell Dev Biol (2015) 0.78
Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target? Oncologist (2012) 0.78
Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα. Genes Dev (2016) 0.78
Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity. Proc Natl Acad Sci U S A (2016) 0.77
Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumors. Mod Pathol (2015) 0.77
Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome. Expert Opin Orphan Drugs (2014) 0.77
Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. Oncotarget (2015) 0.77
Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol (2011) 0.76
Tumor Suppressor Folliculin Regulates mTORC1 through Primary Cilia. J Biol Chem (2016) 0.76
Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells (2016) 0.75
Genetic predisposition to kidney cancer. Semin Oncol (2016) 0.75
Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression. Oncotarget (2017) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Rags to riches: Amino acid sensing by the Rag GTPases in health and disease. Small GTPases (2016) 0.75
FLCN Maintains the Leucine Level in Lysosome to Stimulate mTORC1. PLoS One (2016) 0.75
Recurrent spontaneous pneumothoraces and bullous emphysema. A novel mutation causing Birt-Hogg-Dube syndrome. Respir Med Case Rep (2016) 0.75
Control of B lymphocyte development and functions by the mTOR signaling pathways. Cytokine Growth Factor Rev (2017) 0.75
Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation. Front Pharmacol (2017) 0.75
[Hereditary renal cell carcinomas]. Pathologe (2010) 0.75
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nat Commun (2017) 0.75
FLCN: The causative gene for Birt-Hogg-Dubé syndrome. Gene (2017) 0.75
Lessons from hereditary colorectal cancer. Cell (1996) 25.73
A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics (2001) 15.03
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol (2004) 11.39
Recombineering: a powerful new tool for mouse functional genomics. Nat Rev Genet (2001) 8.35
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15
Cancer-susceptibility genes. Gatekeepers and caretakers. Nature (1997) 5.87
PTEN: one gene, many syndromes. Hum Mutat (2003) 5.79
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol (1977) 4.56
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet (2005) 3.94
Cdk2 knockout mice are viable. Curr Biol (2003) 3.92
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Analysis of Fgf8 gene function in vertebrate development. Cold Spring Harb Symp Quant Biol (1997) 3.51
Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol (2002) 3.28
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. Arch Dermatol (1999) 3.14
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest (2005) 2.94
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69
Clinical and genetic studies of Birt-Hogg-Dubé syndrome. J Med Genet (2002) 2.65
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer (2007) 1.74
A minimal Ksp-cadherin promoter linked to a green fluorescent protein reporter gene exhibits tissue-specific expression in the developing kidney and genitourinary tract. J Am Soc Nephrol (2002) 1.72
A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum Mol Genet (2003) 1.66
Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol (2007) 1.66
Uncompensated polyuria in a mouse model of Bartter's syndrome. Proc Natl Acad Sci U S A (2000) 1.59
A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc Natl Acad Sci U S A (2004) 1.40
The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 1.38
The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe. J Biol Chem (2007) 1.34
A novel renal carcinoma predisposing gene of the Nihon rat maps on chromosome 10. Jpn J Cancer Res (2001) 1.23
Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. J Invest Dermatol (2007) 1.21
Hereditary multifocal renal cystadenocarcinomas and nodular dermatofibrosis in the German shepherd dog: macroscopic and histopathologic changes. Vet Pathol (1985) 1.12
Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma. J Pathol (2007) 1.09
Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Lab Invest (2006) 1.00
Intercalated cells as a probable source for the development of renal oncocytoma. Virchows Arch B Cell Pathol Incl Mol Pathol (1988) 0.93
Developmental expression of ROMK in rat kidney. Am J Physiol (1999) 0.92
Potassium depletion increases proton pump (H(+)-ATPase) activity in intercalated cells of cortical collecting duct. Am J Physiol Renal Physiol (2000) 0.88
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46
Genomic instability in mice lacking histone H2AX. Science (2002) 10.23
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
von Hippel-Lindau disease. Lancet (2003) 6.20
The amsterdam declaration on fungal nomenclature. IMA Fungus (2011) 5.86
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A (2003) 4.47
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science (2009) 4.16
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Cdk2 knockout mice are viable. Curr Biol (2003) 3.92
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol (2010) 3.55
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Bcl11a is essential for normal lymphoid development. Nat Immunol (2003) 3.48
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol (2002) 3.28
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum Mol Genet (2008) 3.14
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. J Clin Invest (2005) 2.94
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat Genet (2009) 2.84
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease. Nat Genet (2013) 2.71
High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst (2005) 2.70
Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. Cancer Cell (2007) 2.69
Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med (2010) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Hematopoietic, angiogenic and eye defects in Meis1 mutant animals. EMBO J (2004) 2.55
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet (2002) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Neuronal release of proBDNF. Nat Neurosci (2009) 2.36
Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity (2005) 2.35
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology (2012) 2.33
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. Nat Immunol (2008) 2.29
The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature (2005) 2.29
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28